التفاصيل البيبلوغرافية
| العنوان: |
Pharmacogenetic Interventions Improve the Clinical Outcome of Treatment-Resistant Autistic Spectrum Disorder Sufferers |
| المؤلفون: |
Arranz, MarÃa Jesús, Salazar, Juliana, Bote, Valentin, Artigas-Baleri, AlÃcia, Serra-Llovich, Alexandre, Triviño, Emma, Roige, Jordi, Lombardia, Carlos, Cancino, Martha, Hernandez, Marta, Cendros, Marc, Duran-Tauleria, Enric, Maraver, Natalia, Hervas, Amaia, Universitat Autònoma de Barcelona |
| سنة النشر: |
2022 |
| المجموعة: |
Universitat Autònoma de Barcelona: Dipòsit Digital de Documents de la UAB |
| مصطلحات موضوعية: |
ASD, Antidepressants, Antipsychotics, Anxiolytics, Personalisation of treatment, Pharmacogenetic intervention, Pharmacotherapy |
| الوصف: |
Autistic spectrum disorders (ASD) are severe neurodevelopmental alterations characterised by deficits in social communication and repetitive and restricted behaviours. About a third of patients receive pharmacological treatment for comorbid symptoms. However, 30-50% do not respond adequately and/or present severe and long-lasting side effects. Genetic variants in CYP1A2, CYP2C19, CYP2D6 and SLC6A4 were investigated in N = 42 ASD sufferers resistant to pharmacological treatment. Clinical recommendations based on their pharmacogenetic profiles were provided within 24-48 h of receiving a biological sample. A total of 39 participants (93%) improved after the pharmacogenetic intervention according to their CGI scores (difference in basal-final scores: 2.26, SD 1.55) and 37 participants (88%) according to their CGAS scores (average improvement of 20.29, SD 11.85). Twenty-three of them (55%) achieved symptom stability (CGI ≤ 3 and CGAS improvement ≥ 20 points), requiring less frequent visits to their clinicians and hospital stays. Furthermore, the clinical improvement was higher than that observed in a control group (N = 62) with no pharmacogenetic interventions, in which 66% responded to treatment (difference in CGI scores: −0.87, SD 9.4, p = 1 × 10; difference in CGAS scores: 6.59, SD 7.76, p = 5 × 10). The implementation of pharmacogenetic interventions has the potential to significantly improve the clinical outcomes in severe comorbid ASD populations with drug treatment resistance and poor prognosis. |
| نوع الوثيقة: |
article in journal/newspaper |
| وصف الملف: |
application/pdf |
| اللغة: |
English |
| تدمد: |
19994923 |
| Relation: |
Pharmaceutics; Vol. 14 Núm. 5 (may 2022), p. 999; https://ddd.uab.cat/record/290517; urn:10.3390/pharmaceutics14050999; urn:oai:ddd.uab.cat:290517; urn:scopus_id:85130120599; urn:articleid:19994923v14n5p999; urn:pmid:35631585; urn:pmc-uid:9143818; urn:pmcid:PMC9143818; urn:oai:pubmedcentral.nih.gov:9143818 |
| الاتاحة: |
https://ddd.uab.cat/record/290517 |
| Rights: |
open access ; Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. ; https://creativecommons.org/licenses/by/4.0/ |
| رقم الانضمام: |
edsbas.4C10DD81 |
| قاعدة البيانات: |
BASE |
Full Text Finder